When a sponsor hands a contract research team a spreadsheet of concentrations, the document usually travels further than the compound ever will. It is copied into method files, pasted into a laboratory notebook, transcribed onto a bench sheet and, eventually, read by someone who was not in the room when the plan was written. That is exactly where a routine dilution table can drift into language it was never meant to carry. A concentration plan should describe how a known material is diluted into a defined volume of medium for an in-vitro assay. The moment it starts to read like a schedule of quantities for a living subject, it has left the scope of research-use-only supply and entered territory a compliant contract team should refuse to touch.
Where a concentration ends and a dose begins
A concentration is a ratio: mass of material per unit volume of a named solvent or medium, within a defined vessel. It says nothing about a subject, a route, a frequency or a body weight, because none of those variables belong in an in-vitro workflow. A dose, by contrast, is a quantity delivered to a living organism over time, and it depends on pharmacology, absorption, metabolism and regulatory frameworks that sit entirely outside the remit of a laboratory supplier or a materials manager.
The distinction matters commercially as well as scientifically. Research Sciences describes its catalogue as research-use-only material for controlled in-vitro work, labelled “For Research Use Only – Not for Human Consumption”, and states that it does not provide therapeutic, medical, performance, injection, ingestion or dosing guidance, and that orders inconsistent with its compliance standards may be refused. Those are the shop’s stated positions rather than legal advice, but they set a useful tone for anyone commissioning work: the paperwork should match the material. A contract team that accepts a document containing a dosing column has, by implication, accepted a brief it cannot deliver.
Ambiguity creeps in through vocabulary rather than intent. A sponsor writes “10 µg” in a column headed treatment, meaning 10 µg/mL final in a 96-well plate; the receiving technician reads a quantity per subject and the document stalls in review. Equally common is the opposite error: a genuine in-vitro plan is rewritten by a well-meaning coordinator into “administration” language because it sounds more professional. Both directions are avoidable if the plan is built around assay endpoints from the first draft and every number carries its unit and its denominator. Concentration language is not a courtesy to the supplier; it is the technical specification of the experiment.
Anatomy of a handover pack that stays in vitro
A defensible handover pack answers dilution questions and deliberately leaves biological questions unanswered. Start with identity: the compound name, the catalogue SKU and the vial label reference, which follows a SKU-plus-expiry format such as BPC10-03/27. That reference links the physical vial to its batch documentation, and quoting it when contacting the supplier about documentation removes guesswork. Ask the receiving laboratory to open the Certificate of Analysis that accompanies the specific batch before anything is weighed, diluted or aliquoted, and to reconfirm any published figure — the shop’s homepage currently describes “≥99% Verified Purity” and lists “CoAs Janoshik Analytical Reports”, but the batch CoA is the document that governs the vial in hand.
Next, specify the stock. State the intended stock concentration in mg/mL, the exact diluent by catalogue name — the site lists both 10ml Mixing Water and Bacteriostatic Water 10ml — and the ambient-temperature equilibration step before reconstitution in a research setting. Follow with the dilution series that produces the final assay concentrations, showing the arithmetic rather than only the result, and include vehicle-only control wells so that solvent effects are separated from compound effects. Where a study requires several compounds, note that Research Sciences does not supply blended peptides and recommends purchasing individual vials and combining them only inside a controlled experimental design; materials managers restocking a defined panel can review the current range and Buy peptides against the approved protocol, then return to each product page for batch documentation.
Finally, document handling as laboratory workflow rather than convenience. Lyophilised material is stored at −20 °C or below, sealed with desiccant and protected from moisture, heat and light; reconstituted material is less stable and is held at 2–8 °C for short-term laboratory use only, with repeated freeze–thaw cycles avoided by single-use aliquots. Record that peptides contain trace mannitol as an excipient, note that vial cap colour is not an indicator of identity or analytical quality, and state that all items remain not for human or veterinary use. A pack containing these elements cannot easily be misread as a dosing schedule, because every line points back to a plate, a well and a volume.
Review gates, red flags and change control
The strongest safeguard is a review gate with a short, unambiguous checklist. Before a concentration plan is released to the bench, a second reviewer confirms that every numeric value carries a unit and a matrix, that no column header implies a subject or a route, and that no instruction describes how a material would be given to a person or an animal. Any document that fails is returned to the sponsor with a specific question, not a general objection. Where the free reconstitution calculator is used to check dilution arithmetic, it stays firmly inside that in-vitro context: it is described as a laboratory research tool and must not be used for human or veterinary dosing under any circumstances.
Change control protects the same boundary. When a sponsor amends a concentration range mid-study, the amendment should re-enter through the same gate, with a new version number, a dated record and a fresh check of the batch CoA if a different vial or Internal Test Reference is introduced. Restocked products may carry the same ITR as earlier stock; an ITR links to associated sample testing reports but does not confirm that separate deliveries share a production lot or received separate independent testing. Treating a restock as a like-for-like substitution without checking documentation is how unintended variables enter an assay.
Materials managers carry a parallel duty that is easy to overlook: lawful use, safe handling, storage and disposal, and compliance with relevant UK regulations including COSHH and laboratory safety standards. Storage containers, labelled aliquots and segregated waste streams are procurement decisions as much as bench decisions, and they belong in the handover pack alongside the dilution table. A pack that specifies the container, the storage temperature, the disposal route and the documentation trail is one that a contract team can accept, cost and schedule without guessing.
Language discipline is the cheapest control available. A short red-flag list — words such as administer, dose, subject, cycle, protocol in a clinical sense — can be applied to every incoming document in seconds, and a standing clause in the service agreement can make clear that concentration plans are accepted only as in-vitro specifications. Sponsors rarely object; most are relieved that someone is reading the numbers with the same care they applied to generating them.
Harare jazz saxophonist turned Nairobi agri-tech evangelist. Julian’s articles hop from drone crop-mapping to Miles Davis deep dives, sprinkled with Shona proverbs. He restores vintage radios on weekends and mentors student coders in township hubs.